Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
Bcr-Abl Inhibitors & Modulators

### AST 487
**(NVP-AST 487)**  
**Cat. No.:** HY-15002  
**Bioactivity:** AST 487 is a RET kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC_{50} of 520 nM.  
**Purity:** >98%  
**Clinical Data:** Size: 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg

### Bafetinib
**(INNO-406; NS-187)**  
**Cat. No.:** HY-50868  
**Bioactivity:** Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC_{50} of 5  
**Purity:** 99.27%  
**Clinical Data:** Size: 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg

### Bosutinib
**(SKI-606; SKI606; SKI 606)**  
**Cat. No.:** HY-10158  
**Bioactivity:** Bosutinib (SKI-606) is a novel Src/Abl inhibitor with IC_{50} of 1  
**Purity:** 99.83%  
**Clinical Data:** Phase 2, Phase 3  
**Size:**

### Dasatinib
**(BMS-354825; BMS354825; BMS 354825)**  
**Cat. No.:** HY-10181  
**Bioactivity:** Dasatinib is a potent and dual Abl^{WT}/Src inhibitor IC_{50} of 0.6 nM/0.8 nM respectively; also inhibits c-Kit^{WT}/c-Kit^{D816V} with IC_{50} of 79 nM/37 nM.  
**Purity:** 99.84%  
**Clinical Data:** Phase 3, Phase 4  
**Size:** 10mM x 1mL in DMSO,  
100 mg, 200 mg, 500 mg

### Dasatinib (hydrochloride)
**(BMS-354825 hydrochloride; BMS354825 hydrochloride; BMS 354825 hydrochloride)**  
**Cat. No.:** HY-10181A  
**Bioactivity:** Dasatinib hydrochloride is a potent and dual Abl^{WT}/Src inhibitor IC_{50} of 0.6 nM/0.8 nM respectively; also inhibits c-Kit^{WT}/c-Kit^{D816V} with IC_{50} of 79 nM/37 nM.  
**Purity:** 99.67%  
**Clinical Data:** Phase 2  
**Size:** 10mM x 1mL in DMSO,  
100 mg, 200 mg, 500 mg

### DCC-2036
**(Rebastinib; DCC 2036; DCC2036)**  
**Cat. No.:** HY-13024  
**Bioactivity:** DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl^{WT} and Abl^{T315I} with IC_{50} of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.  
**Purity:** >98%  
**Clinical Data:** Phase 1  
**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg

### DPH
**Cat. No.:** HY-12070  
**Bioactivity:** DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.  
**Purity:** >98%  
**Clinical Data:** Size: 10mM x 1mL in DMSO,  
10 mg, 50 mg

### Flumatinib
**Cat. No.:** HY-13904  
**Bioactivity:** Flumatinib is a multi-kinase inhibitor with IC_{50} Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.  
**Purity:** 99.83%  
**Clinical Data:** Phase 3  
**Size:** 10mM x 1mL in DMSO,  
5 mg, 10 mg, 50 mg

### Flumatinib (mesylate)
**Cat. No.:** HY-13905  
**Bioactivity:** Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC_{50} Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.  
**Purity:** 99.93%  
**Clinical Data:** Size: 10mM x 1mL in DMSO,  
500 mg

### GNF-2
**(GNF 2; GNF2)**  
**Cat. No.:** HY-11007  
**Bioactivity:** GNF-2 is a highly selective non-ATP competitive inhibitor of oncogenic Bcr-Ab1 activity (IC_{50} = 0  
**Purity:** 94.88%  
**Clinical Data:** Size: 10mM x 1mL in DMSO,  
5 mg, 50 mg
| **GNF-5**  
(GNF 5; GNF5) | **Cat. No.: HY-15738** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>GNF-5, an analogue of GNF-2 with improved pharmacokinetic properties, is a selective non-ATP competitive inhibitor of Bcr-Abl with an IC50 value of 0</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98.0%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **GNF-7**  
(GNF 7; GNF7) | **Cat. No.: HY-10943** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.64%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **GZD824**  
(GZD 824; GZD824) | **Cat. No.: HY-15666** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315D) with IC50 of 0.34 nM and 0.68 nM, respectively.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</td>
</tr>
</tbody>
</table>

| **Imatinib**  
(STI571; STI 571; STI-571) | **Cat. No.: HY-15463** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Imatinib is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit WT with IC50 of 100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.64%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 500 mg</td>
</tr>
</tbody>
</table>

| **Imatinib (Mesylate)**  
(CGP-57148B; STI-571) | **Cat. No.: HY-50946** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit WT with IC50 of 100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.9%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 4</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 200 mg, 500 mg, 1 g, 5 g</td>
</tr>
</tbody>
</table>

| **Nilotinib**  
(AMN-107; Tasigna; AMN107) | **Cat. No.: HY-10159** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Nilotinib is a second generation tyrosine kinase inhibitor (TKI), is significantly more potent against BCR-ABL than Imatinib, and is active against many Imatinib-resistant BCR-ABL mutants.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.93%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 4</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg</td>
</tr>
</tbody>
</table>

| **Nilotinib (monohydrochloride monohydrate)**  
(AMN-107; AMN107) | **Cat. No.: HY-10159A** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.91%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Phase 4</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg</td>
</tr>
</tbody>
</table>

| **Nocodazole**  
(Oncodazole; R17934) | **Cat. No.: HY-13520** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, which exhibits good potency against ABL, ABL(E255K), and ABL(T315I) with IC50 values of 0.21 μM, 0.53 μM, and 0.64 μM, respectively, and increases CRISPR/Cas9-mediated editing frequencies.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.05%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **ON 146040**  
(ON-146040; ON146040) | **Cat. No.: HY-12338** |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong></td>
<td>ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways, inhibits PI3K α/δ isoforms with IC50 of 14/20 nM.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>&gt;98%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>Size: 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

www.MedChemExpress.com
**PD173955**  
(PD-173955)  
Cat. No.: HY-10395  

**Bioactivity:** PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.  

**Purity:** 99.88%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg

---

**Ponatinib**  
(AP-24534; AP24534; AP-24534)  
Cat. No.: HY-12047  

**Bioactivity:** Ponatinib is a potent, orally available multi-targeted kinase inhibitor with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.  

**Purity:** 99.53%  
**Clinical Data:** Phase 2, Phase 3  
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

---

**WP1130**  
(Degrasy; WP 1130; WP-1130)  
Cat. No.: HY-13264  

**Bioactivity:** WP1130 inhibits the autoactivation of Bcr-Abl by inducing its rapid down-regulation with IC50 of 1.8 μM. WP1130 also in a deubiquitinase inhibitor.  

**Purity:** >98.0%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**XL228**  
(XL-228; XL 228)  
Cat. No.: HY-15749  

**Bioactivity:** XL228 is a protein kinase inhibitor targeting IGF1R, the Aurora kinases, FGFR1-3, ABL and SRC family kinases.  

**Purity:** 99.22%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**ZM 306416**  
(CB 676475; ZM-306416; ZM 0616; CB-676475; CB676475)  
Cat. No.: HY-13785  

**Bioactivity:** ZM-306416(CB 676475) is a VEGFR inhibitor that inhibits Flk-1 (KDR) (IC50=100 nM) and Flt (IC50 =2 μM); displays 4-fold selectivity over FGFR-1, inhibitor of c-Abl, Flt-1 and Src.  

**Purity:** 99.8%  
**Clinical Data:**  
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg

---

Tel: 609-228-6898  
Fax: 609-228-5909  
Email: sales@medchemexpress.com